Follicular helper T cells (T FH s) are a key component of adaptive immune responses as they help antibody production by B cells. Differentiation and function of T FH cells are controlled by the master gene BCL6, but it is largely unclear how this transcription repressor specifies the T FH program. Here we asked whether BCL6 controlled helper function through down-regulation of specific microRNAs (miRNAs). We first assessed miRNA expression in T FH cells and defined a T FH -specific miRNA signature. We report that hsa-miR-31-5p (miR-31) is down-regulated in T FH ; we showed that BCL6 suppresses miR-31 expression by binding to its promoter; and we demonstrated that miR-31 inhibits the expression of molecules that control T-helper function, such as CD40L and SAP. These findings identify a BCL6-initiated inhibitory circuit that stabilizes the follicular helper T cell program at least in part through the control of miRNA transcription. Although BCL6 controls T FH activity in human and mouse, the role of miR-31 is restricted to human T FH cell differentiation, reflecting a species specificity of the miR-31 action. Our findings highlight miR-31 as a possible target to modulate human T cell dependent antibody responses in the settings of infection, vaccination, or immune dysregulation. This process ensures the development of long-lived humoral immunity after infection or vaccination with T cell-dependent (TD) antigens and is a unique feature of the mammalian immune system (1). T FH cells were firstly described as a subset of CD4 + T cells present in human lymphoid tissues characterized by the expression of high levels of the C-X-C chemokine receptor type 5 (CXCR5) that allows them to relocate from the T cell zone to the B cell follicles where they primarily provide help to B cells (2). T FH cells can be distinguished from other CD4 + T cell subsets by their low expression levels of cytokines (IFN-γ, IL-4, and IL-17) and transcription factors (T-bet, GATA3, and RORγt) characteristic of Th1, Th2, and Th17 cells, respectively. The B cell lymphoma 6 protein (BCL6) is the master transcription factor of T FH as it directs expression of a unique combination of molecules that are critical for the T FH function, including high levels of the chemokine receptor CXCR5, the inducible T cell costimulator (ICOS), the CD40 ligand (CD40L), the B-and T-lymphocyte attenuator (BTLA), the cytokine IL-21, and the cytoplasmic adaptor protein SLAMassociated protein (SAP) (3, 4). Since BCL6 is a transcriptional repressor thanks to the ability of its BTB/POZ domain to recruit corepressors like BCOR (5), it has been theorized that it enhanced expression of T FH -specific molecules through the down-regulation of specific microRNAs that would otherwise suppress the molecules crucial for T FH to deliver help to B cells (6).
Follicular helper T cells (T FH s) are a key component of adaptive immune responses as they help antibody production by B cells. Differentiation and function of T FH cells are controlled by the master gene BCL6, but it is largely unclear how this transcription repressor specifies the T FH program. Here we asked whether BCL6 controlled helper function through down-regulation of specific microRNAs (miRNAs). We first assessed miRNA expression in T FH cells and defined a T FH -specific miRNA signature. We report that hsa-miR-31-5p (miR-31) is down-regulated in T FH ; we showed that BCL6 suppresses miR-31 expression by binding to its promoter; and we demonstrated that miR-31 inhibits the expression of molecules that control T-helper function, such as CD40L and SAP. These findings identify a BCL6-initiated inhibitory circuit that stabilizes the follicular helper T cell program at least in part through the control of miRNA transcription. Although BCL6 controls T FH activity in human and mouse, the role of miR-31 is restricted to human T FH cell differentiation, reflecting a species specificity of the miR-31 action. Our findings highlight miR-31 as a possible target to modulate human T cell dependent antibody responses in the settings of infection, vaccination, or immune dysregulation. This process ensures the development of long-lived humoral immunity after infection or vaccination with T cell-dependent (TD) antigens and is a unique feature of the mammalian immune system (1) . T FH cells were firstly described as a subset of CD4 + T cells present in human lymphoid tissues characterized by the expression of high levels of the C-X-C chemokine receptor type 5 (CXCR5) that allows them to relocate from the T cell zone to the B cell follicles where they primarily provide help to B cells (2) . T FH cells can be distinguished from other CD4 + T cell subsets by their low expression levels of cytokines (IFN-γ, IL-4, and IL-17) and transcription factors (T-bet, GATA3, and RORγt) characteristic of Th1, Th2, and Th17 cells, respectively. The B cell lymphoma 6 protein (BCL6) is the master transcription factor of T FH as it directs expression of a unique combination of molecules that are critical for the T FH function, including high levels of the chemokine receptor CXCR5, the inducible T cell costimulator (ICOS), the CD40 ligand (CD40L), the B-and T-lymphocyte attenuator (BTLA), the cytokine IL-21, and the cytoplasmic adaptor protein SLAMassociated protein (SAP) (3, 4) . Since BCL6 is a transcriptional repressor thanks to the ability of its BTB/POZ domain to recruit corepressors like BCOR (5), it has been theorized that it enhanced expression of T FH -specific molecules through the down-regulation of specific microRNAs that would otherwise suppress the molecules crucial for T FH to deliver help to B cells (6) .
MicroRNAs (miRNAs) are noncoding single-stranded small RNA molecules that control gene expression posttranscriptionally by binding the 3′ untranslated region (UTR) of target messenger RNA (mRNA). This results in the degradation of target mRNA or inhibition of its translation (7) . In the cells of the immune system, miRNAs have the potential to broadly influence the molecular pathways that control the development and function of innate and adaptive immune responses (8) . Several miRNAs are differentially expressed in T FH cells compared with other T-helper (T H ) cell subsets. Differently from other T H subsets that can still be generated from naïve miRNA-deficient CD4 + T cells, miRNAs are essential for the up-regulation of CXCR5 and the down-regulation of the CC-chemokine receptor 7 (CCR7) during early stage in T FH cell differentiation (9) . Despite the evident crucial role of miRNAs in T FH biology, so far only a few studies in murine models have provided insights into the roles of individual miRNAs or miRNA families in T FH cells and very little is known about the role of miRNAs in human T FH cells (9, 10) .
We therefore asked whether BCL6-regulated miRNAs exist that suppressed expression of molecules key to T FH effector function. Here we analyzed miRNA expression patterns in T FH and CD4
+ naïve T cells from secondary lymphoid organs (SLOs), defining a T FH -specific signature composed of 17 miRNAs. Among them, we show that hsa-miR-31-5p (miR-31) is specifically and strongly down-regulated in human T FH cells in comparison with CD4 + naïve T cells from SLO and with other T cell subsets from peripheral blood (PB). This T FH cell-specific miRNA is able to Significance Antibody production by B lymphocytes generally requires help by T follicular helper (T FH ) cells, a specific subset of CD4 + T lymphocytes. The function of T FH cells depends on BCL6, a transcriptional repressor whose target genes that account for the helper activity are unknown. By the combined analysis of microRNA (miRNA) and gene expression profiling in human T FH cells, we found that miR-31, a miRNA that inhibits gene transcripts relevant for T FH cells biology, is down-regulated in T FH . BCL6 contributes to "helperness" by shutting down miR-31 gene expression, thus stabilizing the follicular helper T cell program. Thus miR-31 is a therapeutic target to modulate human T cell-dependent antibody responses in immunomediated disorders. modulate the expression of molecules that are relevant for T FH cell biology, such as BTLA, SAP, and CD40L, and this in turn compromises the ability of T FH cells to provide B cell help. Finally, we showed that the expression of miR-31 is regulated by BCL6, which binds and represses the activity of the miR-31 host gene promoter (MIR31HG), a long noncoding transcript in which the miR-31 is located.
Results
Down-Regulation of miR-31 in Human T FH Cells Is Mediated by BCL6.
To identify miRNAs specifically modulated in primary human GC T FH cells, we sorted CD4
+ naïve T cells and T FH from adenoids (SI Appendix, Fig. S1 and Table S3 ), assessed their miRNA expression by TaqMan low-density arrays (TLDAs), and performed differential expression analyses. We defined a T FH -specific signature made of 17 miRNAs that are up-or down-regulated in T FH cells compared with naïve T cells (Fig. 1A) . Among the downregulated miRNAs, hsa-miR-31-5p (miR-31) showed the highest fold change between T FH and CD4
+ naïve T cells (SI Appendix, Fig. S2 ). Validation by RT-qPCR on T FH isolated from SLOs of an independent set of individuals confirmed that miR-31 was strongly down-regulated in human T FH cells in comparison not only to CD4
+ naïve T cells (Fig. 1B ) but also to other effector lymphocyte subsets isolated from SLO or peripheral blood (Fig. 1C) .
We then investigated how miR-31 expression is regulated in human T FH cells. Human miR-31 is located in the first intron of the miR-31 host gene (MIR31HG, LOC554202) (Fig. 1D ). To investigate the promoter region of MI31HG in human CD4
+ T cells, we analyzed the histone modifications of the MIR31HG genomic region in CD4
+ naïve T cells and T FH cells. In CD4 + naïve T cells, we found high levels of H3K4me3 and low levels of H3K4me1, i.e., a signature of transcriptionally active promoters (11) (Fig.  1D) . In T FH cells we observed enrichment of both H3K4me3 and H3K27me3, a bivalent modification that is characteristic of transcriptionally poised promoters (Fig. 1D) . Interestingly, when we differentiated naïve T cells in vitro using a cytokine mixture that has been reported to favor T FH differentiation (12), we observed an inverse relation between BCL6 and miR-31 expression (SI Appendix, Fig. S3 ). We therefore asked whether miR-31 downmodulation in T FH cells could be directly mediated by BCL6. To test this hypothesis, we assessed the presence of BCL6 binding sites in the MIR31HG promoter region. We thus performed in silico predictions for BCL6 binding sites in a region of 2,500 bp up-stream of the MIR31HG transcription start site (TSS) using Matinspector from Genomatix software. The sequence analyses of this region revealed eight predicted BCL6 binding sites upstream of the TSS of MIR31HG ( Fig. 1D and SI Appendix, Tables S4 and  S5 ). Interestingly, assessment of a BCL6 ChIP-seq dataset from human primary T FH cells (accession no. GSE59933) revealed a BCL6 peak in the promoter area of MIR31HG (13). To further prove that BCL6 bound to this specific region within the MIR31HG promoter, we performed electrophoretic mobility shift assay (EMSA). Nuclear extracts obtained from HEK293T cell lines stably expressing either wild-type BCL6 or BCL6 deleted from the zinc finger DNA binding domain (BCL6ΔZF) (SI Appendix, Fig. S4A ) were incubated with double-stranded oligonucleotide probes corresponding to MIR31HG promoter or to a known BCL6 binding site (14) . Binding to the MIR31HG promoter was observed only with nuclear extracts from HEK293T stably expressing wild-type BCL6 but not with extracts from cells stably expressing BCL6ΔZF; specificity was confirmed by the reduction of binding observed in presence of specific antibodies for BCL6 (15) (Fig. 1E and SI Appendix, Fig.  S4B ). To further confirm BCL6-mediated regulation of miR-31, we cloned upstream of a luciferase reporter gene the MIR31HG minimal promoter from −415 to −40 (fragment I) and the 5′-flanking sequence from −2,208 to −40 (fragment II) containing the predicted mir-31 gene promoter BCL6 binding sites. We transfected the reporter constructs in HEK293T cells stably transfected with an inducible BCL6 transgene. Upon BCL6 induction, we observed a decrease in transcriptional activity of the fragment containing the putative BCL6 binding sites (fragment II) over the control (fragment I), which correlates with an increasing amount of BCL6 protein levels, further confirming BCL6-mediated regulation of miR-31 gene transcription (Fig. 1F) . We next expressed BCL6 by lentivirus transduction in human CD4
+ naïve T cells ( Fig. 1G ) and observed a statistically significant down-modulation of both pri-miR-31 and mature miR-31 transcripts compared with mocktransduced cells (Fig. 1H ). Altogether our findings indicate that, in human CD4 + T cells, BCL6 can repress miR-31 expression by binding to regulatory regions in its locus.
miR-31 Targets CD40L, SAP, and BTLA mRNAs. To understand a possible inhibitory role miR-31 could have on the effector function of T FH cells, we sought to identify the mRNAs regulated by miR-31. Global transcriptome analysis showed that top miR-31-predicted mRNA targets were derepressed in T FH compared with the same analysis performed on all genes (SI Appendix, Fig. S5A ). To further investigate this issue, we combined target prediction with whole transcriptome analysis by RNA-seq to search for transcripts that were predicted targets of miR-31 and whose expression in T FH cells was inversely correlated with the expression of miR-31, and found 422 anticorrelated expressed and predicted target transcripts ( Fig. 2A and Dataset S1). We then interrogated this list of possible miR-31 targets for potential biological functions in T FH biology by mapping biomolecular networks based on known pathways, gene ontology, and interactions ( Fig. 2B and SI Appendix, Fig. S5B ), and found five genes (CXCR5, CD40L, SAP, BTLA, and CD28) which have an established role in T FH biology and function (16) . We then assessed the inhibitory effect of miR-31 on these six genes by cloning their 3′-UTRs after a luciferase reporter gene and cotransfecting these constructs into HEK293T cells along with synthetic mature miR-31 double-stranded RNA or a control miRNA with scrambled sequences. We found that miR-31 regulates the 3′-UTRs of CD40L, BTLA, and SAP (SI Appendix, Fig. S5C ), three molecules crucial for the helper activity of T FH and their cross-talk with B cells (16) (17) (18) . We also assessed the direct regulation of the three targets in gain-of-function experiments after overexpression of miR-31 in T FH cells; the expression of CD40L, BTLA, and SAP transcripts was assessed by quantitative RT-PCR 3 d after transducing T FH cells with lentiviral vector expressing miR-31 or a control lentivirus ( Fig. 3 A and B) . Importantly, increased expression of miR-31 resulted in significantly lower expression of all three transcripts (20-50%; Fig. 3C ) as well as in a decrease of CD40L, SAP, and BTLA protein levels as measured by cytofluorimetric analysis (Fig. 3D) . shown to contribute to several Ab-mediated autoimmune diseases.
Here we showed that "helperness," of T FH is enforced by BCL6 through the repression of miR-31. We showed that miR-31 modulates expression of CD40L, SAP, and BTLA. CD40L is the key molecule in the B-helper activity of T FH cells, since the binding of CD40 on B cells rescues B cells from apoptosis and promotes their proliferation (19) , while SAP is necessary for CD4 + T cells to form stable contacts with cognate B cells to promote their activation and differentiation (20) . The importance of these molecules is further underscored by the finding that loss-of-function mutations of CD40L and SH2D1A (the gene encoding for SAP) in humans severely compromise the generation of robust GC reactions and subsequent long-lived serological memory (21) . On the other hand, BTLA is an inhibitory receptor important for controlling the size of GC T FH cell pools (22) . Our study indicates that human T FH cell differentiation is, at least in part, dependent on the control of miR-31 transcription by BCL6. However, we cannot make broader claims on BCL6 function and its transcriptional targets in human T FH in this present work. The broad analysis we performed on human T FH miRNome and transcriptome, however, provides clues for future studies on the regulation of the gene networks that control human T FH differentiation and function.
While BCL6 is also the master gene of mouse T FH cells, mouse CD4 + T cell subsets do not show the peculiar expression of miR-31 we observed in human T cell subsets (SI Appendix, Fig. S6 ). Examples of BCL6-regulated miRNAs have been described in mouse lymphocytes, such as miR-155 and miR-361 that target AID and other factors involved in the maintenance of the B cell GC phenotype (23), or miR-17 ∼ 92 that targets CXCR5 in primary T cells (6) although more recent data have outlined different targets of miR-17 ∼ 92 in T FH cells (9, 10) . Our findings suggest that even if the overall molecular mechanisms that lead to T FH cell differentiation are conserved between mice and humans, the discordant expression of miR-31 reflects species-specific differences, as the miRNomes of human and mouse lymphocytes and their target mRNAs are not completely conserved in expression and function (24) .
In conclusion, miR-31 expression in T FH cells is turned off by BCL6 to enforce helper activity that would be modulated by miR-31 through suppression of molecules such as CD40L and SAP. Therefore, modulation of miR-31 activity in T FH cells represents a molecular target for the development of novel and more efficacious strategies to modulate T cell-dependent antibody responses for the therapy of several autoimmune diseases.
Materials and Methods
Purification of Human Lymphocyte Subsets from Peripheral Blood and SLO. Buffy coats and tonsils were obtained from healthy donors at the Istituto di Ricovero e Cura a Carattere Scientifico Policlinico Cà Granda. The ethical committee of Istituto di Ricovero e Cura a Carattere Scientifico Policlinico Cà
Granda approved the use of mononuclear cells from donors for research purposes, and informed consent was obtained from all subjects. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll centrifugation. Lymphocyte subsets were purified by sorting by various combinations of surface markers (SI Appendix, Table S3 ) on a FACS Aria Flow Cytometer (BD).
RNA Isolation and Sequencing. Total RNA isolated from six biological replicates was extracted using mirVana miRNA Isolation Kit (Ambion). Sequencing libraries were prepared and sequenced on an Illumina HiSeq2500. Differential expression analysis (T FH vs. CD4 naïve) was performed using DESeq2 and T FH cells considering a threshold of 1% false discovery rate (FDR) (BenjaminiHochberg correction) and fold change >1.5. The resulting genes were evaluated to be a hsa-miR-31-5p target using TargetScan v.7.0. A total of 422 genes were defined as anticorrelated expressed predicted targets (ACEPTs) hsa-miR-31 genes. A Gene Ontology (GO) enrichment analysis on these target genes was performed using ClueGO Cytoscape.
Profiling of miRNA Expression. Western Blot. Western blotting antibodies are as follows: anti-BCL6 antibody (sc-858, Santa Cruz Biotechnology) and anti-RNA pol II (sc-899, Santa Cruz Biotechnology). Detection was performed using Fluorescent Image Analyzer Fla-9000.
Lentivirus Transduction. miR-31 direct targets were analyzed by FACS with the following antibodies: VioBlue-CD154 (clone 5C8, Miltenyi Biotec), APC-CD272 (clone MIH26, Biolegend), and PE-SAP (clone XLP-1D12, eBioscience). CD4 + naïve T cells from buffy coats obtained from seven healthy donors were transduced with either control lentiviral vector (LVV MOCK GFP) or lentiviral vector encoding BCL6 (LVV BCL6 GFP) in the presence of IL-2 20 units/mL (Miltenyi) and IL-7 2 ng/mL (Peprotech). Cells were sorted as GFP + using FACS Aria (BD).
T FH in Vitro Differentiation Protocol. After overnight stimulation of naïve CD4 + T cells with anti-human CD3-CD28 Dynabeads (Invitrogen), cells were transferred to flat-bottomed 96-well plates and supplemented with human recombinant cytokines: hIL-1β (10 ng/mL), hIL-6 (25 ng/mL), hIL-12 (1 ng/mL), hIL-23 (25 ng/mL), and hTGF-β (5 ng/mL). After 3 d, cells were harvested and BCL6 and miR-31 expression was determined by RT-qPCR. The data were normalized to the values in the culture with no cytokines for each experiment. ELISA. ELISA plate detection antibodies are as follows: biotin mouse antihuman IgG, clone G18-145, 555785 BD, or biotin goat anti-human IgM, B1265 Sigma. Absorption was read at 490 nm with an ELISA reader.
Purification of Mouse Lymphocytes Subsets from Spleens. Five C57BL/6 mice were infused with OT-II thymocytes and challenged with ovalbumin plus alum as adjuvant. After 1 wk, mice were killed and spleens were used as the source of T FH and naïve CD4 T cells. RNA was isolated and miR-31 expression was assessed by RT-qPCR.
